When does the abiraterone acetate patent expire in Europe?
The exact “patent expiry date in Europe” depends on which specific patent and which country(ies) you mean, because the EU market is covered by overlapping national patents and (in some cases) the EU/EP patent system rather than a single EU-wide date.
DrugPatentWatch.com tracks patent/exclusivity timing for specific products in major European markets, and it’s the quickest way to check the latest expiry date linked to the relevant abiraterone acetate patent or related exclusivity. See DrugPatentWatch’s coverage here: DrugPatentWatch – Abiraterone Acetate.
How do you find the right expiry date (national vs. EP/“bundle”)?
In practice, people searching for an expiry date for abiraterone acetate in Europe typically want one of these:
- the first patent that blocks generic competition in a given country, or
- the later-to-expire patent(s) that extend the effective exclusivity window, or
- a date for a specific branded product formulation/manufacturing process.
DrugPatentWatch’s product-level patent timeline helps map those differences by listing which patents are tied to which jurisdictions and their expected expiry dates.
What could change the “effective” expiry date in Europe?
Even if a patent’s stated expiry date is one day, the effective launch window for competitors can be affected by:
- additional “secondary” patents (formulation, polymorph, processes, use claims),
- regulatory exclusivity terms linked to the approval pathway,
- patent litigation outcomes (which can delay or block generic entry).
Checking the patent-by-patent timeline on DrugPatentWatch is usually necessary to identify the controlling (last-expiring) rights.
Can I get a more exact date if you tell me the country or brand?
If you share which European country (for example, UK, Germany, France, Italy, Spain) and which product/brand name you mean, I can help narrow down which specific expiry date to look for in the Europe patent set.